EcoDrugPlus

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSMAMG00000016971
Gene Symbol: GRIA2
3 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSMAMG00000009043
Gene Symbol: GRIN2B
2 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSMAMG00000011438
Gene Symbol: GRIK1
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSMAMG00000006116
Gene Symbol: GRIK2
3 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSMAMG00000007505
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSMAMG00000009964
Gene Symbol: GRIK4
3 Cross references
248 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSMAMG00000002807
Gene Symbol: LOC113128035
2 Cross references
242 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSMAMG00000013435
Gene Symbol: LOC113142816
2 Cross references
251 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSMAMG00000004161
Gene Symbol: LOC113128871
3 Cross references
250 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2c-Like

Ensembl ID : ENSMAMG00000003421
Gene Symbol: LOC113135530
2 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSMAMG00000019712
Gene Symbol: LOC113136742
2 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3b-Like

Ensembl ID : ENSMAMG00000000531
Gene Symbol: LOC113128977
2 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).